The SCFA butyrate was administered through drinking water or intranasally in BALB/c mice to evaluate its role in the ILC2-driven inflammatory response in IL- 33 and Alternaria alternata models of allergic inflammation. We further confirmed our findings in human ILC2s. Results: We show that butyrate, but not acetate or propionate, inhibited IL-13 and IL-5 production by murine ILC2s. Systemic and local administration of butyrate significantly ameliorated ILC2-driven AHR and airway inflammation. We further demonstrate that butyrate inhibited ILC2 proliferation and GATA3 expression but did not induce cell apoptosis, likely through histone deacetylase (HDAC) inhibition, because trichostatin A, a pan-HDAC inhibitor, exerted similar effects on ILC2s. Importantly, cotreatment with trichostatin A and butyrate did not result in an additive effect. Finally, we show that butyrate reduces cytokine production in human ILC2s. Conclusion: Our findings identify butyrate as a critical regulator of ILC2 proliferation and function through its HDAC inhibitory activity and can serve as a potential therapeutic target for asthma. (J Allergy Clin Immunol 2018;142:1867-83.)
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Allergic asthma is a chronic inflammatory condition associated with hypersensitivity to inhaled antigens and is driven by aberrant innate and adaptive immune responses. The cardinal features of allergic asthma include mucus hypersecretion, pulmonary eosinophilic infiltration, and airway hyperreactivity (AHR). Long-term airway remodeling is also observed in patients with chronic asthma. 1, 2 There is an unmet need to provide effective treatment to prevent disease progression that is attributed in part to a lack of comprehensive understanding of asthma pathogenesis. As such, current treatment focuses on alleviating symptoms by using inhaled corticosteroids and b 2 -adrenergic agonists. 3 T H 2 cells and their associated cytokines, mainly IL-4, IL-5, and IL-13, were initially identified as key players in driving the pathogenesis of allergic asthma. 4 However, recent identification of a new group of lymphocytes termed type 2 innate lymphoid cells (ILC2s) has changed the existing paradigm.
ILC2s are localized primarily at mucosal surfaces and have been found in the lung, skin, gut, and adipose tissue of both mice and human subjects. 5, 6 In the lungs ILC2s drive the development of AHR and pulmonary eosinophilia triggered by allergens, such as Alternaria alternata, and influenza virus infection in a T cell-independent manner 7, 8 and have been associated with corticosteroid-resistant asthma. 9 In addition to their role as effector cells, ILC2s are crucial in bridging the innate and adaptive responses because recent studies demonstrated that ILC2s are essential for initiation of T cell-mediated T H 2 responses. [10] [11] [12] However, unlike T cells, ILC2s lack antigen receptors and are activated rapidly by the epithelially derived cytokines IL-33, IL-25, and thymic stromal lymphopoietin and lipid mediators, including leukotriene D 4 . On activation, these cells proliferate rapidly and produce high levels of the T H 2 cytokines IL-13 and IL-5. 13 The biological mechanisms that dictate ILC2 activation and proliferation and cytokine production have not been fully characterized and thus have been the subject of extensive research in recent years.
Microbial metabolites produced by the intestinal microbiota exert immunomodulatory functions that are beneficial to the host. Among these metabolites, short-chain fatty acids (SCFAs) have emerged into the limelight since the discovery of their role in driving regulatory T (Treg) cell differentiation and maintenance of homeostasis in the gut. 14, 15 SCFAs consist of 2-to 5-carbon (C) weak acids, including acetate (2C), propionate (3C), and butyrate (4C), and are the end products of dietary fiber fermentation by anaerobic bacteria from the phyla Bacteroidetes and Firmicutes, among others. 16, 17 Both propionate and butyrate play a protective role in intestinal inflammation through their direct influence on Treg cells. 14, 15 In addition to their anti-inflammatory properties in the gut, SCFAs have been demonstrated recently to regulate allergic inflammation. For instance, propionate protected against house dust mite-driven allergic airway inflammation by impairing the ability of dendritic cells to promote T-cell effector function. 18 In another study maternal intake of acetate protected adult offspring from allergic airway diseases through epigenetic regulation of forkhead box p3 (Foxp3) in Treg cells. 19 However, the role of SCFAs in the regulation of ILC2-mediated airway inflammation remains unclear.
Here we investigated the effect of SCFAs on ILC2 function in the context of allergic airway inflammation. We found that butyrate, but not acetate or propionate, inhibits cytokine production by ILC2s at the transcription level. We demonstrate further that both systemic and local administration of butyrate attenuated ILC2-driven AHR and eosinophilic inflammation in response to A alternata and IL-33. Mechanistically, butyrate inhibited ILC2 proliferation and cytokine production without affecting cell viability through its histone deacetylase (HDAC) inhibitory activity and not through activation of G-coupled protein receptor (GPR) 41 or GPR43. We also show that butyrate can attenuate cytokine production by human ILC2s in humanized mice. Taken together, this study sheds new light on the immunomodulatory role of butyrate in the regulation of ILC2 function.
2 mg of IL-33 was administered intraperitoneally for 5 days, and mice were killed 24 hours later.
In vivo butyrate treatment
Mice were given drinking water containing 150 mmol/L butyrate (Sigma-Aldrich, St Louis, Mo) at pH 7.5 or saline as a control from 3 weeks of age for 6 weeks before exposure to A alternata or IL-33 and throughout the study. Drinking water was replaced twice a week. Alternatively, intranasal administration 10 mmol/L butyrate or saline was performed daily 2 days before exposure to A alternata or IL-33 and throughout the study.
Measurement of airway AHR and collection of bronchoalveolar lavage fluid
Mice were anesthetized with pentobarbital (Sigma-Aldrich) at 20 mg/kg body weight. Lung function of tracheotomized and mechanically ventilated mice was determined by means of direct measurement of airway resistance in response to increasing methacholine (Sigma-Aldrich) doses through the FinePointe RC system (Buxco Research Systems, Wilmington, NC). Bronchoalveolar lavage fluid (BALF) was collected after evaluation of lung function. For further details, see the Methods section in this article's Online Repository at www.jacionline.org.
Lung and blood sample processing for flow cytometry
Lung and blood samples were harvested and processed as described in the Methods section in this article's Online Repository.
Cell sorting and flow cytometry
Single-cell suspensions were processed for flow cytometric analysis, as described in the Methods section in this article's Online Repository. Murine ILC2s were sorted from Rag2 2/2 mice given 0.1 mg of IL-33 for 3 consecutive days and rested for 3 days to obtain sufficient numbers of lung ILC2s for sorting. Naive lung ILCs were sorted from untreated Rag2 2/2 mice. Sorting of IL-33-activated ILC2s and naive innate lymphoid cells (ILCs) was performed with a FACSAria cell sorter (BD Biosciences, Mountain View, Calif) with a sorting purity of greater than 95%.
Isolation and culture of human ILC2s
Human PBMCs were obtained from healthy human donors by using Ficoll-Paque PLUS (GE Healthcare, Uppsala, Sweden) and subjected to lineage depletion with an autoMACS column (Miltenyi Biotec, Bergisch Gladbach, Germany). Human ILC2s were sorted with a FACSAria III cell sorter (BD Biosciences). Cells were cultured in RPMI 1460 supplemented with IL-2 (50 ng/mL), IL-7 (50 ng/mL), and IL-33 (100 ng/mL).
Humanized mice
Adoptive transfer of PBMCs into NSG mice was performed, as previously described, 20 with modifications. Briefly, PBMCs were isolated from whole blood by means of separation over a Histopaque density gradient and injected intravenously into NSG mice at a density of 1 3 10 7 cells per mouse. Butyrate (10 mmol/L per mouse per day) was administered intranasally, whereas recombinant human IL-33, IL-2, and IL-7 (500 ng per mouse per day) were administered by means of intraperitoneal injection for 3 days. Mice were killed 24 hours later.
Statistical tests
Statistical analyses were performed with Prism 6 software (GraphPad software, La Jolla, Calif). Two-way ANOVA and the Student 2-tailed t test were used to determine statistical significance between groups, where P values of less than .05 were considered significant.
Study approval
Animal studies were approved by Academia Sinica Institutional Animal Care and Use Committee, and all experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee. Informed consent was obtained from each donor as requested and approved by the Academia Sinica Institutional Review Board.
Additional information on the methods used in this study can be found in the Methods section in this article's Online Repository.
RESULTS

Butyrate inhibits cytokine production by ILC2s in vitro
To determine whether SCFAs can regulate ILC2 function, we first assessed the effect of acetate, propionate, and butyrate on type 2 cytokine production by IL-33-activated ILC2s. Rag2 2/2 mice were pretreated with IL-33 to facilitate ILC2 expansion, and lung ILC2s were sorted as Lin 
ST2
1 cells (see Fig E1, A, in this article's Online Repository at www.jacionline.org). The phenotype of these cells was confirmed further by expression of Thy1.2, inducible costimulator (ICOS), CD25, CD127, GATA3, and KLRG1 (see Fig E1, B) . We treated sorted lung ILC2s with SCFAs in the presence of IL-33 and found that butyrate, but not acetate or propionate, markedly reduced IL-13 and IL-5 levels in the supernatant of cultured ILC2s in a dose-dependent manner (Fig 1, A) .
To determine whether this was due to impaired cytokine production, we performed intracellular staining of IL- 13 (Fig 1, B) . Accordingly, numbers of total IL-13 1 
IL-5
1 ILC2s were reduced by butyrate, but not acetate or propionate, in a dose-dependent manner (Fig 1, C) .
Suppression was found to occur at the transcription level because quantitative real-time PCR analysis showed significant reduction in both Il13 and Il5 mRNA expression levels after 6 hours of treatment (Fig 1, D) . Because these cells were pre-exposed to IL-33 in vivo, we next assessed whether butyrate had a similar effect on naive ILC2s activated in vitro. To this end, we isolated naive ILCs (sorted as Lin 2/2 mice and cultured them with IL-33 in the presence or absence of butyrate. As shown in Fig 1, E, we found that butyrate also reduced IL-13 and IL-5 levels in the supernatants of these cells but not those of IL-17A and IFN-g, suggesting that other ILCs were unaffected.
Systemic administration of butyrate ameliorates ILC2-mediated AHR and lung inflammation IL-13 and IL-5 cytokines produced by ILC2s play a critical role in the development of AHR and eosinophilic inflammation. 8, 10 To assess the physiologic significance of our in vitro data, we used A alternata, a clinically relevant allergen shown to activate ILC2s and trigger AHR and type 2 inflammation in mice. 21 Circulating J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 6 THIO ET AL 1869
SCFAs derived from the intestinal microbiota have been shown to exert a protective effect against allergic airway inflammation.
18,22
Therefore we exposed 3-week-old mice to butyrate through drinking water to mimic circulating SCFAs for 6 weeks before intranasal A alternata exposure (Fig 2, A, protocol 1) . As expected, A alternata administration increased lung resistance, whereas administration of butyrate without allergen challenge did not lead to increased resistance. However, butyrate-treated mice showed lower resistance than their saline-treated counterparts when challenged with A alternata (P < .001; Fig 2, B, solid compared with open triangles). Total eosinophil counts in the BALF of mice receiving butyrate before allergen challenge were also significantly lower than those in mice receiving saline before allergen exposure (Fig 2, C) . Accordingly, levels of IL-13 and IL-5 in the lungs were reduced in A alternata-treated mice pre-exposed to butyrate compared with A alternata-treated mice receiving saline (Fig 2, D) . Flow cytometry revealed that administration of butyrate before allergen challenge reduced the percentage (Fig 2, E) and total number (Fig 2, F (Fig 2, G) , and this is largely attributed to the decrease in total lung eosinophil counts but not other immune cell subsets (see Fig E2 in this article's Online Repository at www.jacionline.org).
In addition to pulmonary ILC2s, we also assessed the effect of butyrate on circulating ILC2s. Mice were treated with butyrate in drinking water for 6 weeks, followed by intraperitoneal injection of IL-33 (Fig 2, A, protocol 2 ). Flow analysis of peripheral blood leukocytes showed that butyrate also reduced the percentage (Fig 2, H) and total number (Fig 2, I ) of IL-33-induced peripheral blood ILC2s. These data suggest that butyrate can inhibit both lung and circulating ILC2s.
Local administration of butyrate ameliorates ILC2-mediated AHR and lung inflammation
Although circulating SCFAs can inhibit allergic airway inflammation, 22 this effect might be due to exposure of circulatory immune cells to SCFAs rather than direct contact of SCFAs with lung immune cells, as previously suggested. 21 To rule out this possibility, we administered butyrate through the intranasal route, which allows more direct targeting of the lung mucosal immune cells. 23 Butyrate was administered daily 2 days before A alternata exposure and throughout the study (Fig 3, A) . Similar to circulating butyrate, local administration of butyrate also partially suppressed AHR (P < .001; Fig 3, B, solid compared with open triangles), total BALF cell counts (Fig 3, C) , total BALF eosinophil counts (Fig 3, D , and see Fig  E3, A in this article's Online Repository at www.jacionline.org), and type 2 cytokine levels in both BALF (Fig 3, E) and lung tissue (Fig 3, F) . Numbers of BALF T cells and, to a lesser extent, B cells were also reduced in percentage on butyrate exposure under inflammatory conditions (see Fig E3, B) . Flow cytometric analysis revealed a decrease in total numbers (Fig 3, G) and percentages (Fig 3, H) of A alternata-induced lung ILC2s on butyrate treatment. Although we observed a slight decrease in the number of steady-state ILC2s with butyrate treatment, this is likely due to the overall decrease in numbers of total leukocytes (Fig 3, I ), particularly eosinophils, neutrophils, and T and B cells (see Fig E3, C and D) , because the population percentage did not differ between the saline-and butyrate-treated groups (Fig 3, H) . Consistent with these findings, butyrate pretreatment ameliorated allergen-induced epithelial thickening (Fig 3, J and K) , as well as IL-13-mediated mucus hypersecretion (Fig 3, J and L) , as determined by using hematoxylin and eosin and periodic acid-Schiff staining, respectively.
Both colonic and lung Treg cells can be induced by SCFAs, including butyrate. 15, 22 Treg cells have been demonstrated to ameliorate ILC2-mediated AHR and airway inflammation. 24 Hence, to exclude the role of Treg cells, we first examined whether butyrate administration led to Treg cell induction in the lungs. We did not observe an increase in the Treg cell population when butyrate was administered through drinking water (Fig 4,  A) . Although A alternata significantly increased the lung Treg cell population, butyrate treatment did not further increase percentages (Fig 4, A) or total numbers (Fig 4, B) . When administered intranasally, butyrate decreased Treg cell numbers (Fig 4, C) but not percentages (Fig 4, D) at steady state, suggesting that the reduction in Treg cell numbers, as with ILC2 numbers (Fig 3, G) , was due to an overall decrease in total lung leukocyte counts. We further assessed the ability of butyrate to suppress ILC2-mediated AHR in Rag2 2/2 mice, which lack B and T cells, including Treg cells. Similar to wild-type mice, intranasal administration of butyrate could inhibit A alternata-induced AHR in these knockout mice (P < .001; Fig Importantly, total BALF lymphocytes, which include ILC2s, were suppressed (Fig 4, H) . Accordingly, levels of BALF IL-13 and IL-5 were significantly lower in allergen-exposed mice receiving butyrate compared with allergen-exposed mice receiving saline (Fig 4, I ). The observed suppression correlated with the inhibition of allergen-induced lung ILC2 expansion (Fig 4, J) .
To further confirm the role of butyrate in suppressing ILC2-dependent AHR, we treated wild-type mice with IL-33,
Butyrate, but not acetate or propionate, inhibits cytokine production in ILC2s. ILC2s (Fig 1, A-D) were sorted from the lungs of IL-33-treated Rag2 2/2 mice, whereas total ILCs (Fig 1, E) were sorted from naive SEMs of 2 independent experiments (n 5 5-7 each). *P < .05, **P < .01, and ***P < .0001.
an epithelially derived cytokine that specifically activates ILC2s and causes AHR. 25 To this end, we treated the mice daily with butyrate administered through the intranasal route 2 days before IL-33 administration and throughout the study (see Fig E5, A, in this article's Online Repository at www.jacionline.org).
As with the allergen model, pre-exposure to butyrate significantly but partially inhibited IL-33-induced AHR (P < .01; see Fig E5 , B, solid circles compared with solid triangles), as well as total BALF cell counts (see Fig E5, C) , BALF eosinophil counts (see Fig E5, D) , and levels of lung IL-5 and IL-13 (see Fig E5, E) , which corresponded to the reduction in total ILC2 numbers (see Fig E5, F) . Overall, these data confirm that butyrate plays an inhibitory role in ILC2-mediated AHR and lung inflammation. (Fig 3, C) and eosinophils (Fig 3, D) in BALF. E and F, IL-5 and IL-13 levels in BALF (Fig 3, E) and lung homogenates (Fig 3, F ) of mice. G and H, Total number (Fig 3, G) and percentage (Fig 3, H) (n 5 5-6 each). *P < .05, **P < .01, and ***P < .0001.
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Butyrate has been shown to inhibit proliferation and induce apoptosis in various immune and nonimmune cell types. 26, 27 To evaluate whether butyrate exerts similar effect on ILC2s, we sorted lung ILC2s and cultured them with IL-33 in the absence or presence of butyrate. Analysis of cell viability by using fixable viability dye (FVD) staining revealed that butyrate did not induce significant cell death at a concentration of 1 mmol/L or less (Fig 5, A) 28 increased only slightly (<5% at 1 mmol/L) in a dose-dependent manner (Fig 5, B) and is therefore unlikely to have caused the marked decrease in mRNA and protein levels of IL-13 and IL-5 (Fig 1, A and D) . (Fig 4, B) or the intranasal route (Fig 4, C) (Fig 4, F) , eosinophils (Fig 4, G) , and lymphocytes (Fig 4, H mouse. Data are shown as means 6 SEMs of 3 independent experiments (n 5 5-7 each). n.s., Not significant. *P < .05, **P < .01, and ***P < .0001.
We then assessed the proliferation rate of ILC2s by using Ki-67 and carboxyfluorescein succinimidyl ester (CFSE) staining. As expected, IL-33 treatment increased the proliferation capacity of ILC2s when compared with unstimulated control cells, as indicated by the increase in the percentage of Ki-67 1 cells (Fig 5, C) . Butyrate treatment markedly decreased the percentage of Ki-67
1 ILC2s, causing near-complete inhibition at a dose of 0.5 mmol/L. The inhibition was sustained for up to 5 days, as determined by using CFSE staining (Fig 5, D) .
We next assessed the effect of butyrate on the expression of GATA3 in ILC2s activated with IL-33 and treated with butyrate in vitro. Butyrate treatment reduced GATA3 expression in terms of mean fluorescence intensity as early as 6 hours after treatment in a dose-dependent manner (Fig 5, E , and see Fig E6, A and B, in this article's Online Repository at www.jacionline.org). A minimum dose of 0.5 mmol/L was required for the inhibition, which corresponded to the dose required to inhibit cytokine production at the mRNA and protein levels (Fig 1, A and D) . Likewise, the expression of Gata3 mRNA was significantly reduced by butyrate treatment (Fig 5, F) . Butyrate also inhibited the expansion of IL-33-induced GATA3
1 ILC2s from the pool of naive ILC culture at a minimum concentration of 0.25 mmol/L (Fig 5, G , and see Fig E6, C) . Inhibition of proliferation was also observed at this dose, as evident by the reduction in total ILC numbers (Fig 5, H) , although this was not attributed to cell death (Fig 5, I) .
We further confirmed these findings in vivo by using the allergen model. ILC2s were exposed to butyrate through intranasal delivery and challenged with A alternata, as in Fig 3, A. Similar to our in vitro findings, butyrate can ameliorate GATA3 induction by A alternata (Fig 5, J, and see Fig E6, D) . Under steady-state conditions, a majority of lung ILC2s were negative for Ki-67 staining. Allergen challenge significantly increased the Ki-67
1 population, with a fraction of ILC2s expressing high levels of Ki-67 (Fig 5, K) . Importantly, butyrate treatment reduced this population, as well as the overall percentage of Ki-67 1 ILC2s (Fig 5, L) .
Butyrate does not affect pathways downstream of IL-33/ST2 signaling
To investigate the mechanism by which butyrate exerts its inhibitory function, we first evaluated the activation state of several proteins downstream of IL-33/ST2 signaling. Multiplex bead array analysis on the phosphorylation state of 4 kinases (p38, Akt, extracellular signal-regulated kinase [ERK] , and c-Jun N-terminal kinase) downstream of the ST2 receptor revealed no significant difference between butyrate-treated and untreated ILC2s activated with IL-33 (see Fig E7, A-D, in this article's Online Repository at www.jacionline.org). Additionally, IL-33 induced nuclear factor kB (NF-kB) phosphorylation to the same extent in the presence or absence of butyrate (see Fig E7,  E) . These data suggest that butyrate does not affect IL-33/ST2 signaling pathways.
GPR41 activation does not affect ILC2 function
SCFAs have been shown to activate GPR41 (FFAR3) and GPR43 (FFAR2), although butyrate preferentially activates GPR41. 29, 30 We assessed the expression of GPR41 in ILC2s and found that IL-33 treatment significantly upregulated mRNA levels of GPR41 when compared with control values, and butyrate cotreatment did not affect expression levels (Fig 6, A) . To determine the role of GPR41 activation on ILC2 function, we treated IL-33-activated ILC2s with the GPR41 agonist AR420626 and measured cytokine levels in the supernatant. Unlike butyrate, AR420626 treatment did not attenuate the levels of IL-33-induced IL-13 and IL-5 (Fig 6, B) . Furthermore, flow cytometric analysis of Ki-67 revealed no significant differences between untreated and AR420626-treated ILC2s, suggesting that the agonist does not impair ILC2 proliferation (Fig 6, C) . Likewise, expression of GATA3, which was induced by IL-33, was not affected by AR420626 treatment (Fig 6, D) . In addition, AR420626 treatment did not affect the ability of butyrate to inhibit IL-13 and IL-5 production by ILC2s (Fig 6, E) . Overall, these results imply that GPR41 activation does not affect ILC2 function or proliferation and that the inhibitory effect of butyrate is likely to be GPR41 independent.
We also evaluated the effect of GPR43 activation on ILC2 function. Similar to GPR41, IL-33 upregulated the mRNA level of GPR43, although this was inhibited by butyrate (see Fig E8, A, in this article's Online Repository at www.jacionline.org). We found that 4-CMTB, a GPR43 agonist, increased ILC2 cell proliferation in a dose-dependent manner (see Fig E8, B) but had no effect on GATA3 expression (see Fig E8, C) . Interestingly, however, IL-13 and IL-5 levels in the supernatant were reduced by 4-CMTB treatment (see Fig E8, D) . More importantly, butyrate cotreatment with 4-CMTB resulted in synergistic inhibition, suggesting that butyrate does not go through the GPR43-mediated pathway.
Butyrate exerts its inhibitory effects through HDAC inhibition
Aside from activation of GPRs, SCFAs also exhibit HDAC inhibitory activity and can induce histone acetylation in multiple cell types. [31] [32] [33] To determine whether butyrate acts as an HDAC inhibitor in ILC2s, we analyzed the levels of H3 acetylation and HDAC activity in comparison with trichostatin A (TSA), a well-established HDAC inhibitor. Although IL-33 has been shown to induce histone acetylation in some cell types, such as mast cells, 34 no notable increment in total H3 acetylation was observed in ILC2s treated with the same stimulus. However, both butyrate and TSA treatment significantly augmented the levels of H3 acetylation (Fig 7, A and B) , whereas HDAC activity was reduced in a dose-dependent manner (Fig 7, C) . We also tested the H3 acetylation effect of acetate and propionate and found that although acetate did not alter the level of H3 acetylation, propionate weakly induced H3 acetylation when compared with butyrate (see Fig E9 in this article' s Online Repository at www.jacionline.org).
To investigate the importance of HDAC inhibition in ILC2 function, we treated IL-33-activated ILC2s with increasing concentrations of TSA and evaluated its effect on ILC2 viability, proliferation, and cytokine production. Although TSA treatment at a concentration as high as 10 nmol/L did not affect cell viability (Fig 7, D) , ILC2 proliferation was significantly impaired, as shown by Ki-67 (Fig 7, E) and CFSE staining (Fig 7, F) . Similar to butyrate, GATA3 expression (Fig 7, G, and see Fig E10, A, in this article's Online Repository at www.jacionline.org), as well as Il13 and Il5 mRNA levels (Fig 7, H) , were significantly ameliorated by TSA treatment in a dose-dependent manner, suggesting that HDAC inhibition impaired ILC2 proliferation and function.
To determine whether butyrate-mediated inhibition is dependent on its HDAC inhibitory activity, we cotreated ILC2s with butyrate and TSA in the presence of IL-33. Butyrate has been shown to act on similar HDAC targets as TSA in dendritic cells through cotreatment strategy. 35 Like butyrate, we found that TSA can also inhibit IL-13 and IL-5 production at the protein level. Interestingly, cotreatment of TSA and butyrate did not exhibit any synergistic or additive effects (Fig 7, I) . Accordingly, butyrate treatment did not further enhance TSA-mediated GATA3 inhibition (Fig 7, J, and see Fig E10, B) . These data support the hypothesis that butyrate inhibits ILC2 function through inhibition of HDAC activity.
Butyrate inhibits cytokine production by human ILC2s
To assess the effect of butyrate in human ILC2s, we sorted these cells from PBMCs of healthy donors and cultured them in IL-33 in the absence or presence of butyrate for 3 days. Levels of IL-13 and IL-5 in culture supernatants were measured by means of ELISA. Similar to murine ILC2s, butyrate potently inhibited IL-13 and IL-5 production in human ILC2s (Fig 8, A) . We confirmed these data by using humanized PBMCs from mice treated with IL-33 with or without pre-exposure to butyrate through the intranasal route (Fig 8, B) . ILC2s were gated as the CD45 Fig 8, C) . We found that butyrate treatment reduced the percentage (Fig 8, C , third column) and total number (Fig 8, D) of ILC2s. Importantly, intracellular staining of type 2 cytokines revealed a significant reduction in the percentage (Fig 8, C , fourth and fifth column) and total number (Fig 8, E) of IL-13-and IL-5-producing ILC2s. Notably, butyrate did not alter the percentage (Fig 8, C, first column) or total number (Fig 8, F) of CD3 1 T cells, nor did it affect the overall frequency of IL-13-and IL-5-producing T cells (Fig 8, G) . Collectively, these data suggest that butyrate exerts similar inhibitory effects on human ILC2s.
DISCUSSION
Recent evidence has implicated gut microbial metabolites in the regulation of allergic airway inflammation in the context of adaptive immunity. 14, 15 Although adaptive immunity holds a pivotal role in orchestrating the cardinal features of asthma, ILC2s take central stage in driving acute asthma exacerbations triggered by allergens, such as A alternata. 36 However, the role of microbial metabolites in the regulation of ILC2-driven allergic inflammation has yet to be elucidated. For the first time, we show that the microbial metabolite butyrate directly regulates ILC2 function and attenuates ILC2-mediated AHR and airway inflammation.
SCFAs, such as acetate, propionate, and butyrate, have been shown to promote Treg cell generation in separate studies. 14, 35 Additionally, SCFAs promote naive T-cell differentiation into T H 1 and T H 17 effector cells, 37 whereas their roles in T H 2 responses have been shown to be inhibitory and are mediated through interaction with other immune cells. 18, 22 Here we show that only butyrate inhibited IL-13 and IL-5 production by murine ILC2s. Because high concentrations of butyrate (>1 mmol/L) have been shown to induce cell apoptosis, 38, 39 we further excluded cell death as a possibility for the observed suppression by showing that butyrate treatment (up to 1 mmol/L concentration) did not augment the percentage of apoptotic cells. Importantly, we demonstrate that butyrate can inhibit type 2 cytokine production by human ILC2s transferred into NSG mice.
Recent evidence suggests an inverse correlation between a high-fiber diet and asthma severity in patients. 40 This is supported by the finding that a high-fiber diet increased circulating SCFAs and provided protection against allergic airway disease in mice. 18 Similarly, butyrate administered through drinking water suppressed the cardinal features of allergen-induced inflammation, including AHR, eosinophil infiltration, and T H 2 cytokine release, through inhibition of lung ILC2 expansion. We also show that short-term intranasal administration of butyrate can ameliorate both A alternata-induced AHR and airway inflammation to a similar degree as circulating butyrate. The lung microbiome has been implicated in the orchestration of the outcome of allergic disorders. For instance, SCFA-producing phyla, including Bacteroidetes, Firmicutes, and Fusobacteria, have been identified in the respiratory tracts of healthy subjects and asthmatic patients, and a strong correlation exists between the severity of asthma and microbial dysbiosis in the lungs. 41, 42 Moreover, a recent study showed that bacteria isolated from the lungs can produce SCFAs, although correlation between SCFA production and asthma development remains controversial. 43 Hence our study provides supporting evidence that local production of metabolites can influence the outcome of airway allergy. (Fig 5, A-F) , whereas total ILCs were sorted from naive Rag2 2/2 mice (Fig 5, G-I ). Cells were cultured with 10 ng/mL (Fig 5, A-F) or 50 ng/mL (Fig 5, G-I (Fig 5, K) and percentage Ki-67 1 lung ILC2s (Fig 5, L) . Data are shown as means 6 SEMs from 2 independent experiments (n 5 4-5 each). n.s., Not significant. *P < .05, **P < .01, and ***P < .001.
=
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The total SCFAs in gut lumen is approximately 100 to 150 mmol/L, whereas the concentration of SCFAs in the bloodstream is vastly lower at 0.1 to 1 mmol/L under normal physiologic conditions. [44] [45] [46] This is due to the large uptake of SCFAs by colonic epithelial cells (>95%), with only a small proportion being absorbed into the portal circulation. 45, 47 To mimic the physiologic condition, we fed mice with 150 mmol/L butyrate (drinking water), a concentration previously used by others. 14, 48 Meanwhile, the concentration of lung SCFAs in healthy subjects is not well defined, although it can reach up to (Fig 7, A) and relative expression (Fig 7,  B) of ac-H3 level after 6 hours of treatment. Data were normalized against total H3. C, HDAC activity in ILC2 nuclear extracts after 6 hours of treatment. D, Percentage of viable ILC2s after 48 hours of treatment, as determined by using FVD staining. E and F, Proliferation of ILC2s, as assessed by using Ki-67 (Fig 7, E) and CFSE staining (Fig 7, F) SDs from 1 of 2 to 3 independent experiments (n 5 3 wells) with consistent findings. n.s., Not significant. *P < .05, **P < .01, and ***P < .001.
2 mmol/L in the sputum of patients with cystic fibrosis. 49 Nevertheless, intranasal administration of butyrate at 10 mg/mL (approximately 1 mol/L) has been shown to protect against allergic rhinitis. 50 However, because of concerns with toxicity, we resorted to a lower dose (10 mmol/L). We found that both treatment regimens partially but significantly reduced the ILC2 population and airway inflammation. Because butyrate acted in a dose-dependent manner in vitro, we reasoned that the partial inhibition might be due to the amount of butyrate reaching lung ILC2s, given that it is likely to be taken up by other immune and nonimmune cells either through passive diffusion or GPRs present on other cells, such as bronchial epithelial cells, dendritic cells, and neutrophils. 18, 51, 52 We also observed that butyrate treatment administered through the intranasal route, but not through drinking water, reduced T-and B-cell populations in the lungs at both steady state and during allergen-induced inflammation. This might be due to differences in bioavailability and pharmacokinetic properties between the 2 modes of administration, 53 as well as the final concentration and duration of butyrate exposure in the lungs. Extensive studies will be required to dissect the underlying mechanism of inhibition in these cells, although some studies have shown that butyrate can induce apoptosis in T cells and modulate B-cell differentiation. 54, 55 Nevertheless, the effects of butyrate on both lymphocyte populations do not contribute to its suppressive effect in ILC2s, as demonstrated in our Rag2 2/2 mouse model.
A recent study found that SCFA production by Heligmosomoides polygyrus significantly augments house dust mite-induced lung IL-10 and TGF-b levels and Treg cell suppressor function, although the lung Treg cell proportion was only slightly increased. 22 In this study, however, we did not observe any changes in lung Treg cell Data are shown as means 6 SEMs from 2 independent experiments (n 5 5). n.s., Not significant. *P < .05, **P < .01, and ***P < .001.
numbers after butyrate exposure either through drinking water or the intranasal route. Moreover, no significant increase in levels of lung IL-10 and TGF-b was observed through either method of butyrate administration under allergen-induced inflammatory conditions (data not shown). Importantly, butyrate inhibited ILC2s in the absence of Treg cells, as demonstrated in Rag2 2/2 mice. Therefore, although we do not completely rule out the possibility that butyrate can affect Treg cell function, Treg cells are not required for the inhibitory effects of butyrate on ILC2s in the A alternata model.
We found that butyrate reduced numbers of murine ILC2s in the lungs after IL-33 and A alternata treatment. Likewise, IL-33-induced human ILC2 expansion was attenuated by butyrate treatment in NSG mice. It has been shown previously that A alternata induces ILC2 accumulation in an IL-33-dependent manner. 8 IL-33 promotes local ILC2 proliferation and expansion in the lungs rather than recruitment from other tissues. 56 This led us to hypothesize that butyrate can affect ILC2 proliferation. In support of this, butyrate is known to inhibit proliferation in multiple cell types. 26, 27 Consistent with our hypothesis, we found that butyrate inhibits murine ILC2 proliferation both in vitro and in vivo. In addition, we found that inhibition of IL-13 and IL-5 expression occurred at the transcription level. Because GATA3 is the master regulator for transcription of the Il13 and Il5 genes, 57 we assessed the effect of butyrate on GATA3 expression in vitro. Similar to a previous study, 58 we found that IL-33 could induce GATA3 expression in cultured ILC2s. Although a previous study demonstrated that butyrate does not affect GATA3 expression in T cells, 15 we found that GATA3 expression was attenuated on butyrate exposure at both the protein and mRNA levels. This suppression likely led to impaired cytokine production and attenuated ILC2-induced AHR and lung inflammation.
The anti-inflammatory role of butyrate has been attributed to multiple factors, including inhibition of NF-kB activation in various immune cell types, 59 although a recent study showed that butyrate does not affect NF-kB or mitogen-activated protein kinase signaling pathways downstream of Toll-like receptor 4 in LPS-stimulated macrophages. 60 Similar to this study, we found that butyrate does not affect signaling downstream of the ST2 receptor. We also show that butyrate does not act through either GPR41 or GPR43, both of which are induced by IL-33 at the mRNA level. This is based on the observation that the GPR41 agonist did not affect ILC2 function, whereas the GPR43 agonist and butyrate treatment led to synergistic inhibition of cytokine secretion. Moreover, GPRs have been shown to activate ERK and p38 mitogen-activated protein kinase signaling pathways. 61 However, our bead array data show that butyrate treatment did not induce any increase in ERK and p38 phosphorylation, affirming that butyrate-mediated suppression is independent of GPR activation. Because SCFAs can be readily absorbed into any cell types through simple diffusion or active transportation through soluble transporters, 62, 63 it is likely that butyrate is taken up by ILC2s through either of these mechanisms, thus bypassing the GPR receptors, although more extensive studies will be required to elucidate the pathway involved.
It is widely known that butyrate acts as an HDAC inhibitor in many cell types. In this study we show that both butyrate and TSA, a pan-HDAC inhibitor, augment the level of acetylated H3 at lysines 9 and 14 and inhibit HDAC activity. TSA has been reported to suppress ILC2-mediated allergic inflammation in mice by reducing the number of lung ILC2s. 64 In agreement with this finding, we show that TSA phenocopies the effect of butyrate in terms of attenuating T H 2 cytokine production, GATA3 expression, and proliferation. Importantly, we show that TSA and butyrate cotreatment did not result in synergistic effects, further suggesting that butyrate acts as an HDAC inhibitor in ILC2s. Histone acetylation leads to transcriptional activation because of DNA unwinding, which increases access of basal transcription factors and RNA polymerase II to the promoter region. 65 However, this modification has also been shown to recruit chromatin-repressive complexes, such as Mi-2/NURD, and cause transcriptional inhibition in macrophages. 66 Whether the inhibitory effect of butyrate/TSA is due to direct acetylation of T H 2-related genes or indirectly through transcriptional activation/repression of other targets that can alter the expression of T H 2-related genes warrants further investigation. HDAC inhibitory activity is not limited to butyrate because other SCFAs, such as propionate and acetate, also exhibit such activity, although to a varying degree of potency. Acetate is known to be a weak HDAC inhibitor, 31 whereas the inhibitory activity of propionate has been reported to be lower than butyrate. 67 Indeed, acetate has been shown to exhibit little to no effect on H3 acetylation in dendritic cells, whereas propionate induced H3 acetylation to a lower degree than butyrate. 35 In line with these findings, we observed that acetate did not induce H3 acetylation at 1 mmol/L, whereas H3 acetylation by propionate at a concentration of 1 mmol/L was significantly lower than that caused by butyrate. This likely explains the lack of inhibition by acetate and the slight suppression of IL-5 by propionate at 1 mmol/L in IL-33-stimulated cultured ILC2s (Fig 1, A and B) . In the case of propionate, a higher concentration might be required to achieve a more prominent suppression.
In conclusion, we demonstrate that both local and systemic administration of butyrate inhibit ILC2 proliferation and cytokine production likely through inhibition of GATA3 expression. As a consequence, allergic airway inflammation is attenuated. Mechanistically, we prove that butyrate acts through inhibition of HDACs in a GPR-independent manner. Our work highlights the importance of butyrate as an immunomodulatory metabolite in controlling allergic inflammation. Given that A alternata and ILC2s have been associated with corticosteroid-resistant asthma, 68, 69 this finding might be of potential clinical relevance and might open up new therapeutic avenues for the treatment of corticosteroid-resistant asthma.
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Key messages
d Butyrate directly inhibits ILC2 proliferation and cytokine function through GATA3 inhibition without affecting cell survival.
d Butyrate acts through HDAC inhibition and H3 acetylation independent of GPR41 and GPR43.
d Inhibition of ILC2 function by butyrate ameliorates A alternata and IL-33-mediated AHR and airway inflammation.
d Similar inhibition was observed in human ILC2s both in vivo and in vitro.
METHODS
Measurement of airway AHR and collection of BALF
Mice were anesthetized with pentobarbital (Sigma-Aldrich) at 20 mg/kg body weight. Lung function of tracheotomized and mechanically ventilated mice was determined by means of direct measurement of airway resistance in response to increasing methacholine (Sigma-Aldrich) doses by using the FinePointe RC system (Buxco Research Systems). Immediately after AHR, lungs were lavaged twice with 1 mL of PBS supplemented with 2% FBS (HyClone, Logan, Utah). BALF was pooled and pelleted by means of centrifugation and fixed onto cytospin slides. Slides were stained with Diff-Quik solution (Polysciences, Warrington, Pa), and BALF differential cell counting was performed.
Antibodies, cytokines, and reagents
All antibodies were obtained from BioLegend, unless specified otherwise. The following antibodies were used for flow cytometric staining of murine samples at 1:400 dilution, unless specified otherwise: CD3ε Fluorochrome-conjugated FVD and Ki-67 were purchased from eBioscience. Mouse (anti-CD16/32) and human TruStain FcX (Fc blocking solution) were purchased from BioLegend. Recombinant mouse IL-33, IL-2, and IL-4 were purchased from BioLegend, whereas recombinant mouse IL-7 was obtained from PeproTech (Rocky Hill, NJ). Recombinant human IL-33 and IL-7 were purchased from BioLegend, whereas IL-2 was purchased from eBioscience. Anti-mouse IFN-g (XMG1.2) and IL-12/IL-23 p40 (C17.8) were purchased from BioXcell (West Lebanon, NH). Phorbol 12-myristate 13-acetate (PMA) and ionomycin were obtained from Sigma-Aldrich. Brefeldin A, the Annexin V Apoptosis Detection kit, and the BD Cytofix/Cytoperm kit were purchased from BD Biosciences. The Foxp3 Transcription Factor Staining kit was purchased from eBioscience. CFSE was purchased from Cayman Chemical (Ann Arbor, Mich).
Lung and blood sample processing for flow cytometry
Whole lungs were minced and incubated in Dulbecco modified Eagle medium with 0.1% (vol/vol) DNase I (Worthington Biochemicals, Lakewood, NJ) and 1.6 mg/mL collagenase IV (Worthington Biochemicals) for 40 minutes at 378C. Tissues were filtered through a 70-mm mesh to obtain single-cell suspensions. Red blood cells were removed from the cell suspensions by using ACK lysing buffer (Gibco Laboratories, Grand Island, NY). Single-cell suspensions were resuspended in the appropriate buffer for further processing.
Peripheral blood was collected by means of cardiac puncture in a tube containing 20 mmol/L Na 2 EDTA (Millipore, Billerica, Mass) as an anticoagulant. Mononuclear cells were isolated with Histopaque-1077 (Sigma-Aldrich) and resuspended in the appropriate buffer for further processing.
Cell sorting and flow cytometry
For surface staining, single-cell suspensions were first stained with FVD, followed by Fc blocking with anti-mouse CD16/32 or anti-human TruStain FcX, and then stained with the appropriate antibodies. Intracellular staining was performed, as previously described, with modifications.
E1 Single-cell suspensions from the lungs of mice were stimulated with 100 ng/mL PMA, 1 mg/mL ionomycin, and 1 mg/mL Brefeldin A in DMEM for 6 hours. Alternatively, PMA, ionomycin, and Brefeldin A were added directly to cultured ILC2s during the last 6 hours of culture. After surface staining, cells were fixed and permeabilized with BD Cytofix/Cytoperm solution and further stained intracellularly with anti-mouse or anti-human IL-13 and IL-5. For transcription factor staining, the Foxp3 staining buffer set was used according to the manufacturer's instructions. For detection of apoptotic cells, cells were stained with the Annexin V Apoptosis Detection kit, according to the manufacturer's recommendations. After staining, cells were washed and resuspended in FACS buffer and analyzed by using flow cytometry. Data were acquired on an LSR II (BD Biosciences) and analyzed with FlowJo v.10.1 software (TreeStar, Ashland, Ore).
Murine ILC2s were sorted from Rag2 2/2 mice given 0.1 mg of IL-33 for 3
consecutive days and rested for 3 days to obtain sufficient number of lung ILC2s for sorting. Naive lung ILCs were sorted from untreated Rag2 
In vitro ILC2 and ILC culture
Freshly sorted lung ILC2s were cultured, as previously described, E2 with modifications. Briefly, ILC2s were expanded for 6 days in RPMI 1640 supplemented with 10% FBS, IL-33, IL-2, and IL-7 (all at 10 ng/mL). Cells were rested for 3 days in complete RPMI 1640 medium supplemented with IL-2 and IL-7 (both at 10 ng/mL) before each experiment. In some experiments ILC2s were treated with AR460262 (Cayman Chemical) or 4-CMTB (Tocris Bioscience, Bristol, United Kingdom) at the indicated concentrations and time points.
For ILC culture, cells were sorted and seeded at 1.0 3 10 4 cells/well in 150 mL of culture medium containing IL-33 (50 ng/mL), IL-2, and IL-7 (both at 10 ng/mL) with the appropriate treatment for 5 days.
CFSE labeling
For CFSE labeling, cultured ILC2s (1.5 3 10 4 cells/well in 150 mL of culture medium) were incubated with 5 mmol/L CFSE for 5 days, according to the manufacturer's protocol.
Lung histology
Lungs were fixed with 4% formaldehyde (Merck, Darmstadt, Germany) and gradually dehydrated with 30%, 50%, and 70% ethanol (J.T. Baker). The lungs were embedded in paraffin and stained with hematoxylin and eosin or periodic acid-Schiff stain. Images were acquired with an Olympus CX31 microscope (Olympus, Tokyo, Japan). 
Preparation of lung homogenates for ELISA
T H 2 polarization of OT-II cells
OT-II mice were sensitized with 10 mg of ovalbumin peptide 323-339 (pOVA; InvivoGen, San Diego, Calif) in alum (InvivoGen) for 14 days. T cells from spleens of pOVA-sensitized mice were cultured under T H 2-polarizing conditions, as previously described. Data are shown as means 6 SDs from 1 of 2 independent experiments (n 5 3 wells) with consistent findings. n.s., Not significant. *P < .05, **P < .01, and ***P < .0001. Fig E6, were cultured with IL-33, IL-2, and IL-7 (all at 10 ng/mL) with or without butyrate at indicated concentrations for 10 minutes. Control cells were cultured with IL-2 and IL-7 only (both at 10 ng/mL). A-D, Multiplex bead array analysis of the phosphorylated form of Akt (Fig E7, A) , ERK (Fig E7, B) , c-Jun N-terminal kinase (JNK; Fig E7, C) , and p38 (Fig E7, D) . E, Flow cytometry of phospho-NF-kB. Data are shown as means 6 SDs from 1 of 2 independent experiments (n 5 3 wells) with consistent findings. n.s., Not significant.
